- Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
- Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
- Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
- Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
- Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
- Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
- Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
- Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
- Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
More ▼
Key statistics
On Friday, Disc Medicine Inc (IRON:NMQ) closed at 32.18, 25.70% above the 52 week low of 25.60 set on Apr 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.34 |
---|---|
High | 32.48 |
Low | 31.44 |
Bid | 28.11 |
Offer | 35.00 |
Previous close | 31.92 |
Average volume | 297.57k |
---|---|
Shares outstanding | 24.72m |
Free float | 20.24m |
P/E (TTM) | -- |
Market cap | 795.54m USD |
EPS (TTM) | -3.37 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼